In Angioplasty, Then There Were Three
The US angioplasty business has always been a two-horse race. But the booming stent market has changed all that. With its acquisition of CR Bard's angioplasty business, AVE is angling to become a third major angioplasty player.
You may also be interested in...
Adding non-transfusion-dependent anemia patients to the Reblozyl label is a key strategy for the product, which BMS expects to reach $4bn in annual sales.
Biogen has warned that uptake for its newly approved Alzheimer’s therapy will be slow in the beginning and doctors confirm it will take time to figure which patients can and should be treated.
Public Company Edition: The pace of US initial public offerings slowed a bit in April and May but could ramp back up in June as biopharma investor sentiment rebounds. Also, drug developers continue to go public via SPAC mergers, most recently Valo Health with a $2.8bn post-deal valuation.